TEMPO.CO, Jakarta - PT Kalbe Farma (KLBF) inaugurates the development of its biological drug factory, PT Kalbio Global Medika in Cikarang, Bekasi, with an investment value that ranges between US$30 to US$35 million. The factory, which is built on a 10,000 meters square land, is predicted to begin production activity in Q2 2016.
"The development of the biological drug factory is Kalbe's follow-up to support the creation of an integrated pharmaceutical industry, from raw material, technology control, and attempt to increase export," Kalbe Farma CEO Irawati Setiady said on Wednesday, January 27, 2016.
The factory is built based on a joint-effort between Kalbe and a South Korean pharmaceutical company Genexine Inc. under a joint venture company PT Kalbe-Genexine Biologics. Kalbe owns 40 percent of the company's share, while the rest is owned by Genexine.
The factory will manufacture various bological drugs including vaccine, protein, and anti-body with an annual production capacity of 10.5 million syringe. "This will establish a strong foothold for the Indonesian pharmaceutical industry to win the business competition in ASEAN and global [market]," said Irawati.